InsiderDB

Rep. Daniel S. Goldman sold Gilead Sciences (GILD)

Rep. Daniel S. Goldman (D-NY-10) · $15K–$50K · traded Jul 12, 2023

Transaction
Sold
Amount
$15K–$50K
Owner
Not stated
Traded
Jul 12, 2023
Disclosed
Aug 13, 2023
Days to disclose
32
Asset type
Stock
As filed
Gilead Sciences, Inc.
Industry
Drug Manufacturers - General · Healthcare

Other trades in this filing

All of Goldman's trades →

Recent Congress trades in GILD

Company context for GILD

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. GILDFinancial report·SEC EDGAR

    GILD: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 29, 2026, 8:09 PM EDTEvent / period: Sep 30, 2026Original source ↗
  2. GILDCompany announcement·SEC EDGAR

    GILD: Financial results

    Filed 8-K for an event or period dated 2026-10-29. Financial results.

    Public: Oct 29, 2026, 4:03 PM EDTEvent / period: Oct 29, 2026Original source ↗
  3. GILDLobbying report·Lobbying disclosures

    GILD: third_quarter 2026 lobbying report

    Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Advocate on drug pricing proposals. Proposals to exp

    Public: Oct 21, 2026, 1:36 PM EDTOriginal source ↗

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.